|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,630,000 |
Market
Cap: |
17.88(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$129.52 - $211.15 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
13,210 |
71,441 |
1,221,838 |
5,585,598 |
Total Sell Value |
$2,269,704 |
$11,037,856 |
$218,022,204 |
$1,085,125,139 |
Total People Sold |
6 |
6 |
7 |
10 |
Total Sell Transactions |
8 |
18 |
22 |
56 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Huang Jane |
CMO, Hematology |
|
2021-10-19 |
4 |
AS |
$362.05 |
$559,163 |
D/D |
(1,500) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-10-19 |
4 |
OE |
$119.96 |
$179,940 |
D/D |
1,500 |
1,500 |
|
- |
|
Wang Lai |
Global Head of R&D |
|
2021-09-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
58,188 |
174,551 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-20 |
4 |
AS |
$390.91 |
$2,387,774 |
D/D |
(6,000) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-20 |
4 |
OE |
$119.96 |
$719,760 |
D/D |
6,000 |
6,000 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-15 |
4 |
AS |
$374.39 |
$9,864,173 |
D/D |
(26,158) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-15 |
4 |
AS |
$29.31 |
$5,575,287 |
D/D |
(190,203) |
1,736,904 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-14 |
4 |
AS |
$361.56 |
$13,901,782 |
D/D |
(37,877) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-14 |
4 |
AS |
$28.22 |
$4,447,078 |
D/D |
(157,600) |
2,267,161 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-13 |
4 |
AS |
$355.37 |
$4,620,390 |
D/D |
(12,901) |
0 |
|
- |
|
Amgen Inc |
10% Owner |
|
2021-09-10 |
4 |
B |
$302.06 |
$49,999,938 |
D/D |
165,529 |
18,943,802 |
2.45 |
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-02 |
4 |
S |
$327.18 |
$178,314 |
D/D |
(545) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-02 |
4 |
AS |
$324.50 |
$8,040,809 |
D/D |
(24,499) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
545 |
545 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-01 |
4 |
S |
$310.53 |
$168,307 |
D/D |
(542) |
0 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,124 |
312,948 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-01 |
4 |
AS |
$324.41 |
$8,306,484 |
D/D |
(25,501) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-09-01 |
4 |
AS |
$24.34 |
$3,105,165 |
D/D |
(127,558) |
2,917,162 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
542 |
542 |
|
- |
|
Huang Jane |
CMO, Hematology |
|
2021-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
7,163 |
305,824 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-08-31 |
4 |
AS |
$299.74 |
$10,415,111 |
D/D |
(34,281) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-08-31 |
4 |
AS |
$23.67 |
$1,817,756 |
D/D |
(76,800) |
3,694,720 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-08-05 |
4 |
AS |
$331.64 |
$3,497,744 |
D/D |
(10,362) |
0 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-08-05 |
4 |
AS |
$25.82 |
$880,302 |
D/D |
(34,100) |
4,217,173 |
|
- |
|
Oyler John |
Chief Executive Officer |
|
2021-08-04 |
4 |
AS |
$340.40 |
$10,925,109 |
D/D |
(31,747) |
0 |
|
- |
|
559 Records found
|
|
Page 6 of 23 |
|
|